Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2011-06-02 Investor Presentation
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec AG, Telefonkonferenz zur Akquisition von Compound Focus
Investor Presentation Classification · 98% confidence The document is titled 'Evotec AG, Investor and Analyst call, 1st June 2011' and contains slides detailing an acquisition ('Acquisition of Compound Focus Inc.'), strategic rationale, financial outlook, and an agenda typical of a presentation given to investors or analysts. The structure, use of bullet points, financial figures, and forward-looking statements strongly indicate an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement (RPA/RNS) about a report; it is the presentation material itself.
2011-06-02 English
M&A Activity 2011
M&A Activity Classification · 99% confidence The document is explicitly titled 'EQUITY RESEARCH COMPANY ALERT' and contains detailed analysis, financial projections (KEY DATA), analyst contact information, and extensive regulatory disclosures typical of investment bank research reports. It discusses a specific corporate action (acquisition) and provides a rating ('Buy') and target price. This content aligns best with a general research or analysis document that is not a formal regulatory filing like a 10-K or an Earnings Release (ER). Since it is a detailed analysis/presentation of findings, 'Investor Presentation' (IP) or 'Management Reports' (MDA) might seem plausible, but the structure and explicit labeling as 'Equity Research' strongly suggest it is an analyst's published view. Given the provided categories, this type of document—a detailed, non-regulatory, analyst-driven report—is often categorized under 'Investor Presentation' (IP) if it were a slide deck, or sometimes falls into a broader category. However, looking closely at the definitions, none perfectly capture 'Equity Research Report'. Since it provides detailed financial analysis and outlook, it is closest in function to an Investor Presentation (IP) or a detailed Management Report (MDA). Given the context of an 'Alert' and analysis, and the lack of a specific 'Equity Research' code, I will evaluate the closest fit. It is not a formal company filing (10-K, IR, ER). It is an external analysis. In many databases, detailed external research reports are sometimes grouped with Investor Presentations (IP) or sometimes fall under Regulatory Filings (RNS) if no better fit exists. Since it is a detailed analysis, I will lean towards 'Investor Presentation' (IP) as the best proxy for detailed, forward-looking analysis provided to investors, although 'RNS' is a possibility if it were a mandatory disclosure. Given the depth of analysis and projections, IP is a stronger fit than the general RNS fallback.
2011-06-01 English
Investor Presentation 2011
Investor Presentation Classification · 99% confidence The document is titled "Eine Research-Publikation der DZ BANK AG" (A Research Publication of DZ BANK AG) and contains detailed financial forecasts, valuation metrics (KGV, EV/EBITDA), a revised 'Fair Value' (fairer Wert), and a 'Kaufen' (Buy) recommendation for the stock Evotec. It includes comprehensive P&L statements with projections up to 2015e and detailed key performance indicators (KPIs). This structure is characteristic of an equity research report or investment analysis, not an official regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since 'Investor Presentation' (IP) is usually a slide deck and 'Earnings Release' (ER) is just the initial announcement, this detailed analysis fits best under a general research/analysis category. Given the provided options, this document is a detailed analysis/report, which is closest in nature to an Investor Presentation (IP) if it were a presentation, or perhaps a specialized report. However, since it is explicitly a 'Research-Publikation' providing investment advice and detailed financial models, and there is no specific 'Equity Research Report' code, I must choose the closest fit. It is not a standard regulatory filing. It contains more detail than a typical Fund Factsheet (FS). Given the context of financial analysis and forward-looking statements, 'Investor Presentation' (IP) is often used broadly for detailed investment materials, but the content strongly suggests a formal research report. Since the document is a detailed analysis published by a bank (DZ BANK) and not a company filing, and it is not a transcript (CT) or a formal regulatory announcement (RNS), I will classify it as an Investor Presentation (IP) as it serves the purpose of presenting investment rationale, although it is structured as a written report. Alternatively, if we strictly adhere to the definitions, it doesn't perfectly match any, but it is a detailed financial document. Given the high level of detail and forward-looking estimates, it is more substantial than a simple 'Fund Information / Factsheet' (FS). I will lean towards 'IP' as the best fit for detailed investment rationale material, recognizing it is a research report.
2011-05-19 German
Investor Presentation 2011
Investor Presentation Classification · 95% confidence The document is titled "A Research Publication by DZ BANK AG" concerning the company Evotec. It contains detailed financial forecasts (2011e through 2015e), valuation metrics (PER, EV/Sales), a revised fair value recommendation ("New fair value: EUR 3.50 Euro per share"), and extensive Profit and Loss statements and ratio analyses. This structure is characteristic of an equity research report or investment analysis published by a bank or brokerage firm, not an official regulatory filing (like 10-K, ER, or IR) made by the company itself to the SEC or equivalent body. Since 'Investor Presentation' (IP) is for company-issued materials, and 'Earnings Release' (ER) is for initial company announcements, the best fit for a third-party analyst's detailed report is often classified under a general research category. Given the provided options, this document is a detailed analysis, which aligns most closely with the comprehensive nature of an Investor Presentation (IP) if we interpret it broadly as an in-depth analysis document, or potentially a specialized 'Financial Supplement Data' (XLSX) if it were only data, but it contains narrative and recommendation. However, since it is a detailed, forward-looking analysis published by a third party (DZ BANK), and it is not a standard regulatory filing, it most closely resembles the depth of an Investor Presentation (IP) or a specialized research report. Given the options, and recognizing this is a third-party research document, it is often categorized as an Investor Presentation (IP) in databases that lack a specific 'Equity Research Report' code, as it presents investment rationale and detailed financials. If a more specific code existed for third-party research, that would be preferred. Lacking that, and given its comprehensive nature, IP is the closest fit among the choices for a detailed investment document, although it is technically a research note. I will assign a high confidence score based on the clear identification as a 'Research Publication' with detailed financial projections and recommendations.
2011-05-19 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is explicitly titled "EQUITY RESEARCH COMPANY ALERT" and contains detailed analysis, rating changes (BUY, TARGET PRICE adjustment), financial forecasts (2010 X, 2011E, 2012E tables), analyst certifications, and extensive regulatory disclosures typical of investment bank research reports. This content strongly aligns with an Investor Presentation (IP) or a detailed research report, but given the structure (alert format, target price adjustment, detailed financial modeling commentary), it functions as a comprehensive analysis provided to investors. Since 'Investor Presentation' (IP) covers detailed presentations focusing on financials and strategy, and this document provides deep analytical commentary and valuation adjustments, IP is the most fitting category among the choices, although it is technically an Equity Research Report. It is not a formal regulatory filing like 10-K or ER, nor is it a simple announcement (RPA/RNS).
2011-05-18 English
Investor Presentation 2011
Investor Presentation Classification · 98% confidence The document is a detailed research publication from DZ BANK AG concerning the company Evotec. It contains extensive financial data, forecasts (2011e, 2012e, etc.), analysis of Q1 results, investment recommendations ('Kaufen'), and detailed Profit & Loss statements. This structure—a comprehensive analysis report issued by a financial institution about a publicly traded company, including forward-looking estimates and investment ratings—is characteristic of an Investor Presentation or a detailed Research Report. Since 'Investor Presentation' (IP) is the closest fit for a detailed, non-regulatory, analytical document aimed at investors, it is the most appropriate classification. It is not a standard regulatory filing (like 10-K or IR), nor is it a short announcement (RPA/RNS).
2011-05-13 German

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.